Holen Sie sich die Stockscreener-App
63.82
0.58%
-0.37
Handel nachbörslich:
65.01
1.19
+1.86%
Schlusskurs vom Vortag:
$64.19
Offen:
$64.43
24-Stunden-Volumen:
226.12K
Relative Volume:
0.77
Marktkapitalisierung:
$2.24B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-67.89
EPS:
-0.94
Netto-Cashflow:
-
1W Leistung:
+4.88%
1M Leistung:
+31.43%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$61.55
$65.28
1-Wochen-Bereich:
$57.45
$66.53
52-Wochen-Spanne:
$32.00
$69.41
Veradermics Inc Stock (MANE) Company Profile
Firmenname
Veradermics Inc
Sektor
Branche
Telefon
228.372.3376
Adresse
470 JAMES STREET, NEW HAVEN
Compare MANE vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MANE
Veradermics Inc
|
63.82 | 2.25B | 0 | 0 | 0 | -0.94 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Veradermics Inc Stock (MANE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-03-02 | Eingeleitet | Citigroup | Buy |
| 2026-03-02 | Eingeleitet | Jefferies | Buy |
| 2026-03-02 | Eingeleitet | Leerink Partners | Outperform |
Veradermics Inc Aktie (MANE) Neueste Nachrichten
VeraDermics Surges 9%—Yet Major Investors Remain Cautious - Bitget
MANE SEC FilingsVERADERMICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Veradermics Shares More Than Double in NYSE Debut - MarketScreener
Citi Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $85 - Moomoo
VeraDermics (MANE) Plummets 7% as Intraday Volatility Unfolds — What's Fueling the Sharp Drop? - Bitget
Veradermics (NYSE: MANE) bets on oral minoxidil for pattern hair loss - Stock Titan
Veradermics, Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Veradermics Reports Strong 2025 Financials, Completes Key VDPHL01 Trials, and Raises $295M IPO to Fund Operations Into 2029 - Minichart
Veradermics (NYSE: MANE) deepens 2025 loss after $294.8M IPO cash boost - Stock Titan
MANE: Raised $294.8M in IPO, completed key trial enrollment, and reported a $70M net loss for 2025 - TradingView
Earnings Flash (MANE) Veradermics Posts Q4 Net Loss $21.8M - marketscreener.com
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates - businesswire.com
Jefferies reiterates Buy on Veradermics stock, $75 target By Investing.com - Investing.com Canada
Veradermics, Incorporated(NYSE: MANE) added to S&P TMI Index - marketscreener.com
Veradermics to present hair loss treatment data at AAD meeting By Investing.com - Investing.com South Africa
Veradermics Announces Presentations on VDPHL01 and Patient Experi - The National Law Review
Veradermics to present hair loss treatment data at AAD meeting - Investing.com
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting - Business Wire
Veradermics Inc (MANE) Financial Ratios - Investing.com India
Veradermics (MANE) Stock Analysis Report | Financials & Insights - Benzinga Japan
Is Veradermics (MANE) Pricing Look Attractive After Recent Pharma Sector Reappraisal? - Yahoo Finance
MANE Should I Buy - Intellectia AI
A Look At Veradermics (MANE) Valuation After Recent Share Price Momentum And DCF Upside Signals - simplywall.st
Dermatology drug maker Veradermics set for Miami investor spotlight - Stock Titan
Veradermics, Incorporated: Revenue and Earnings Analysts Forecasts Revisions | MANE | US9229671048 - marketscreener.com
MANE Technical Analysis & ETF Price Forecast - Intellectia AI
Veradermics, Incorporated: Dividend historical data and projections - marketscreener.com
Leerink initiates Veradermics stock with Outperform rating By Investing.com - Investing.com UK
Cantor Fitzgerald Initiates VeraDermics at Overweight - marketscreener.com
Jefferies Initiates VeraDermics at Buy With $75 Price Target - marketscreener.com
Citigroup Initiates VeraDermics at Buy With $85 Price Target - marketscreener.com
Leerink Initiates VeraDermics at Outperform With $75 Price Target - marketscreener.com
Veradermics eyes FDA first as Jefferies initiates at 'buy'; sees 75% upside on oral hair loss pill - Proactive financial news
Leerink initiates Veradermics stock with Outperform rating - Investing.com South Africa
Jefferies initiates Veradermics stock with buy rating on phase 3 prospects - Investing.com Canada
Cantor Fitzgerald initiates Veradermics stock with Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald initiates Veradermics stock with Overweight rating - Investing.com
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell – Company Announcement - Financial Times
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell - Finviz
Assessing Veradermics (MANE) Valuation After Recent Share Price Move And Persistent Pre Revenue Losses - Yahoo Finance
Veradermics completes enrollment in second pivotal phase 3 clinical trial of Vdphl01 for male pattern hair loss - marketscreener.com
Veradermics Completes Enrollment in 2nd Phase 3 Study of VDPHL01 for Male Pattern Hair Loss - marketscreener.com
Veradermics completes enrollment in phase 3 trials for hair loss drug - Investing.com Canada
Completion of VDPHL01 Phase 3 Enrollment for Male Pattern Hair Loss - Intellectia AI
Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss - Business Wire
Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report - biocentury.com
Finance Watch: Four IPOs In One Week - Citeline News & Insights
A sign biotech is back? Four drugmakers go public, raising nearly $1 billion in all - statnews.com
Slate of Biotechs Heads to the Public Markets, Spurring Optimism - WSJ
Veradermics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering - BioSpace
Veradermics completes $294.8 million IPO with full underwriter option exercise - Investing.com
Finanzdaten der Veradermics Inc-Aktie (MANE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):